Head-to-head · WeighScore
Gala Health vs Eden
The verdict
Eden takes it — 90/100 to 86/100.
Eden grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. High-disclosure, high-oversight compounded program with the cleanest verification signals.
Assume any provider we list may compensate us — we may earn a commission at no cost to you. It never changes the WeighScore.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Gala Health | Eden |
|---|---|---|
| WeighScore | 86/100 | 90/100 |
| Grade | B | A− |
| Scorecard rank | #8 | #2 |
| Semaglutide | Not disclosed | $239/mo |
| Tirzepatide | $179/mo | $349/mo |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #8 · B
Strengths
- Low compounded entry — tirzepatide $179/mo, microdose from $149, 3-month plans from $199
- Available in all 50 states
- Keeps a brand-name path open (Ozempic listed at $1,299)
- HRT and menopause care available alongside GLP-1
Where it loses points
- Compounded formulations are not FDA-approved
- Brand-name Ozempic is priced steeply at $1,299
- No oral or sublingual route offered yet
- Newer operator (Gala GLP-1 by AI Coaching Inc) with a shorter public record
Graded #2 · A−
Strengths
- High verification confidence
- Nationwide
- Both molecules
Where it loses points
- Premium pricing
- Compounded only
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 31 providers, CoreAge Rx grades highest at 94/100 (A). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.